Last reviewed · How we verify
CDDP 75
CDDP 75 is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription.
CDDP 75 is a platinum-based chemotherapy drug that works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Ovarian cancer, Testicular cancer, Lung cancer.
At a glance
| Generic name | CDDP 75 |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Holy Name Medical Center, Inc. |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CDDP 75, also known as cisplatin, is a platinum-based chemotherapy drug that works by forming platinum-DNA adducts, which interfere with DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells.
Approved indications
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Bladder cancer
- Stomach cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Renal impairment
- Hearing loss
- Ototoxicity
- Peripheral neuropathy
- Myelosuppression
- Hypersensitivity reactions
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma (PHASE1)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CDDP 75 CI brief — competitive landscape report
- CDDP 75 updates RSS · CI watch RSS
- Holy Name Medical Center, Inc. portfolio CI